Semaglutide denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Quantity Limits to Semaglutide

UnitedHealthcare's quantity-limit (QL) edits for semaglutide define the maximum supply — in pens, injections, or fills — the plan will cover within a given time period. A quantity-limit denial occurs when the prescription as written exceeds those plan-defined limits. This does not always mean more medication is medically unnecessary; it means the plan's standard edit was triggered and a clinical exception must be requested.

Quantity-limit exceptions are routinely granted when the prescriber documents that the prescribed quantity aligns with the FDA-approved dosing schedule in the label and is clinically appropriate for the individual patient.

## Federal Appeal Framework

• Internal appeal / quantity-limit exception — most plans have a parallel "formulary exception" or "quantity-limit exception" process that runs alongside the formal appeal. File both simultaneously to preserve your timeline. ERISA plans must decide standard pre-service appeals within 30 days.
• External review (ACA §2719 / ERISA §503) — if denied internally, independent external review is available, generally within approximately four months of the original denial. Expedited external review is available when the clinical situation is urgent.

## Documentation to Gather

• FDA-approved prescribing label — identify the dosing schedule and titration regimen described in the label for the specific semaglutide formulation prescribed. The prescribed quantity should map to that schedule.
• Prescriber letter of medical necessity — the prescriber should explain why the quantity prescribed is consistent with the label's dosing regimen and the patient's current phase of treatment (e.g., titration vs. maintenance).
• UnitedHealthcare's current quantity-limit policy — obtain the specific limit being applied and the exception criteria, then address each in your appeal.
• Chart documentation of current dosing rationale — notes explaining why the patient is at the prescribed dose/quantity and how long they have been on that regimen.
• Prior-treatment and response history — evidence of how the patient has responded over time, supporting the clinical appropriateness of the current prescription volume.

## Criteria-Mapping Structure

Address the quantity limit directly:

| Plan's Quantity Limit | Prescribed Quantity | Rationale | |---|---|---| | [Limit from UHC policy] | [Qty on prescription] | [Label-consistent titration/maintenance dosing per prescriber note] |

## Key Argument

The core argument is that the prescribed quantity is consistent with the FDA-approved dosing schedule as described in the prescribing label, and that imposing a lower quantity would require the patient to receive a clinically incomplete or interrupted course of treatment. If the patient is in a titration phase requiring more frequent supply, document this explicitly. Quantity limits that conflict with label-directed dosing are routinely overridden on appeal.